ProQR Therapeutics (PRQR) Profit After Tax (2012 - 2026)

ProQR Therapeutics (PRQR) has reported Profit After Tax for 15 consecutive years, with -$15.2 million the latest figure, recorded in Q1 2026.

• Quarterly Profit After Tax fell 32.78% year-over-year to -$15.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$128.3 million (down 1290.59% YoY) and the FY2025 annual result came in at -$48.0 million, down 51.94% from the prior year.
• Profit After Tax advanced to -$15.2 million in Q1 2026 per PRQR's latest filing, from -$85.9 million in the prior quarter.
• Over the last five years, Profit After Tax for PRQR reached as high as $26.5 million in Q3 2022 and fell as low as -$131.0 million in Q4 2022.
• A 5-year average of -$11.4 million and a median of -$5.6 million in 2023 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2022 — Profit After Tax plunged 731.07% — and 2024, when it jumped 247.44%.
• Year by year, Profit After Tax stood at -$131.0 million in 2022, then surged by 95.71% to -$5.6 million in 2023, then slumped by 86.47% to -$10.5 million in 2024, then sank by 719.73% to -$85.9 million in 2025, then soared by 82.26% to -$15.2 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$15.2 million, -$85.9 million, and -$12.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.